The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Douglas Tsao - H. C. Wainwright - Analyst
: Hi, good afternoon. Thanks for taking the question. I guess, Rick, just given sort of the continued outperformance we've seen in TRELEGY and the
likelihood of some additional cash coming in, how are you thinking about, right now, you've talked about the special committee being committed
to returning capital to shareholders. But how much do you potentially need to sort of keep in-house for the potential launch of ampreloxetine.
Question: Douglas Tsao - H. C. Wainwright - Analyst
: And I guess as a follow-up, when we think about the company over the last several years, you've obviously sort of narrowed your focus. Obviously,
we're sort of almost sort of dual goals of maximizing the opportunity with YUPELRI as well as executing on the ampreloxetine study.
I guess when we think about the company over the long term, are there pipeline assets? I mean there were several assets, which I think some
people were interesting, but sort of were put on pause.
And I guess, is that ever sort of come back into the equation, just given you noted the sort of operational or sort of the efficiency in launching
ampreloxetine, and that could just bring significant capital into the company and sort of change your position?
Question: Douglas Tsao - H. C. Wainwright - Analyst
: Okay, great, thank you.
Question: Julian Harrison - BTIG - Analyst
: Hi, Congrats on the quarter. First, I'm curious to what extent that recently published manuscript detailing the MCID for the OHSA composite score
informs your expectations for top line CYPRESS data first quarter of next year.
Any other comments on what you think a win on data would be, would be helpful as well. And then the YUPELRI data, CHEST looked fantastic.
Thinking about that, I'm wondering if you could talk more about how these results are supportive of YUPELRI new patient starts at the hospital call
point.
Question: Julian Harrison - BTIG - Analyst
: Very helpful. Thank you.
Question: Ellen Horste - TD Cowen - Analyst
: Hi guys. Thanks for taking the question, and congrats on the exciting quarter and the progress in the CYPRESS study. My question is about CYPRESS.
So with the open-label portion complete, can you share how many patients have ultimately enrolled in the randomized withdrawal portion?
And if not, can you confirm that this number is sufficient for the powering according to the original trial design? Thank you.
Question: Ellen Horste - TD Cowen - Analyst
: Thank you.
|
